FINWIRES · TerminalLIVE
FINWIRES

ECB June Rate Hike Expectations Build as Spanish Inflation Holds Firm, French Prices Climb in May

By
ECB June Rate Hike Expectations Build as Spanish Inflation Holds Firm, French Prices Climb in May

Steady inflation in Spain and rising prices in France for May are supporting calls for the European Central Bank to lift interest rates at its upcoming June meeting.

In Spain, preliminary data showed consumer prices rose 3.2% year over year in May, matching the previous month's reading and against the consensus estimate from Investing.com of 3.3%. Meanwhile, the nation's annual core inflation rate increased to 2.9% from 2.8%.

The index faced upward pressure from the transport, recreation, sporting and culture sectors, where price drops were softer than in May 2025. On the other hand, clothing and footwear pulled prices lower, while food and non-alcoholic beverages also provided downward relief, with prices remaining stable against the previous year's increases.

Concurrently, France's flash annual inflation rate for May 2026 accelerated to 2.4% from the previous month's 2.2%. While the print came in slightly below the expected 2.5%, inflation increased for the fourth straight month and reached its highest level since February 2024.

The increase was primarily fueled by rising energy costs, with gas prices surging amid the ongoing war in the Middle East.

ECB Executive Board member Isabel Schnabel said in an interview with Reuters published on Tuesday that the central bank will likely need to raise interest rates during its next Governing Council ​meeting starting June 10 to combat a "much more persistent" inflation shock that is "working its way through the economy."

As headline inflation in the euro area hit 3% and is expected to climb toward 4% by year-end, Schnabel warned that "looking through is no longer an option." However, she maintained that the ECB avoids pre-committing to a post-June trajectory, remaining "strictly data dependent."

Following the release of the ECB's April meeting minutes on Thursday, ING highlighted Schnabel's comments as confirmation that a June rate hike is "almost a done deal." ING's global head of macro Carsten Brzeski said a 25-basis-point "insurance rate hike" poses less risk to economic growth than the loss of credibility the ECB would face by "falling behind the curve."

"What's even more interesting is what will happen beyond the June meeting. As long as fiscal stimulus remains muted, the risk of an outright inflationary spiral remains small, making an aggressive monetary policy reaction to the current energy price shock unlikely," Brzeski added.

Related Articles

DHL Taps USPS for Last-mile US Deliveries in New $10 Billion Deal
US Markets

DHL Taps USPS for Last-mile US Deliveries in New $10 Billion Deal

DHL eCommerce, the US unit of German logistics group Deutsche Post (DHL.F), d/b/a DHL Group, further strengthened its 25-year partnership with the United States Postal Service by appointing the latter as its exclusive provider for last-mile parcel deliveries across the US.Under the multi-year deal, valued at more than $10 billion, USPS will manage the final stage of delivery for all DHL eCommerce shipments moving through the company's 19 nationwide hubs, the companies said Thursday. Last-mile delivery refers to the final leg of the supply chain, transporting goods from a distribution hub to customers' doorsteps.DHL eCommerce Americas Chief Executive Scott Ashbaugh said the deal will help the company expand its services while reducing the number of delivery vehicles on the road and lowering emissions.Speaking to reporters during a same-day media webinar, Ashbaugh said the new arrangement differs from the companies' previous contract due to its longer duration, enabling DHL eCommerce to secure longer-term agreements with its customers, Supply Chain Dive reported.The exact length of the multi-year agreement was not disclosed.The deal also provides a financial boost to USPS, which recently warned of a cash crisis and called on Congress to expand its borrowing authority to support operations and long-term stability.Since DHL eCommerce does not prefer investing heavily in developing its own last-mile network in the US, the deal is "a total win-win," Postmaster General and USPS CEO David Steiner said at the webinar.Shares of DHL Group edged higher in early trading in Germany.

$DHL.F
AstraZeneca's Imfinzi Gets US FDA Nod for Bladder Cancer Combo Therapy
US Markets

AstraZeneca's Imfinzi Gets US FDA Nod for Bladder Cancer Combo Therapy

The US Food and Drug Administration approved AstraZeneca's (AZN.L, AZN,ST) Imfinzi, or durvalumab, in combination with another drug for the treatment of non-muscle-invasive blood cancer, or NMIBC, the British drugmaker said Thursday.The approval is based on positive results from the Potomac phase 3 trial, which showed a 32% reduction in the risk of high-risk recurrence, progression, or death after one year of Imfinzi in combination with Bacillus Calmette-Guerin, or BCG, induction and maintenance therapy, compared with BCG alone.The durvalumab-BCG combo is the first therapy to be approved in the US in over 30 years for BCG-naive, high-risk NMIBC. Authorities in the European Union, Japan and other countries are also reviewing regulatory submissions based on the phase 3 trial results, AstraZeneca said.Over 31,000 people were treated for high-risk NMIBC in the US in 2024, according to the drugmaker. Half of patients with the condition are at high risk of experiencing disease recurrence or progression, with up to 80% of high-risk patients seeing recurrence within five years of treatment."Unfortunately, many of these patients experience disease recurrence requiring repeated surgical procedures, as well as disease progression resulting in surgical removal of their bladder," said Neal Shore, director of START Carolinas and a co-principal investigator in the phase 3 trial. "The POTOMAC trial demonstrates that the durvalumab with BCG induction and maintenance regimen reduces the risk of disease recurrence, progression or death for patients by almost a third compared to BCG alone, heralding a marked advancement for patients with high-risk non-muscle-invasive bladder cancer."Imfinzi is also approved in several countries for patients with cisplatin-eligible muscle-invasive bladder cancer.The drug generated $1.69 billion in revenue for AstraZeneca in the first quarter, up 30% year over year at constant exchange rates, making it the second-highest earning product in the company's oncology portfolio, behind Tagrisso.Shares of the drugmaker rose 1% in early trading in London on Friday.

$AZN.L$AZN.ST
Singapore Producer Prices Surge Higher in April
US Markets

Singapore Producer Prices Surge Higher in April

Singapore's producer prices jumped higher in April, propelled by increases on global crude prices, reported Statistics Singapore on Friday.The city-state's manufactured products price index rose 20.2% on year in April, and gained 6.7% from March, said officials. The index measures prices at the factory gate of domestically produced goods.Singapore's manufactured products oil price sub-index rose 68.2% in April on year, and by 4.1% on month, reflecting surging global petroleum prices since the Strait of Hormuz was closed to tanker traffic in February.However, even Singapore's non-oil manufactured products price sub-index rose 21.4% on year in April, and by 7.3% from March, said Statistics Singapore.Chemical prices rose 28% on year in April, reflecting increases in the costs of oil and gas, from which chemicals are often derived.Statistics Singapore also produces a domestic supply price index, designed to measure prices of goods manufactured locally or imported, but which are retained for use in the domestic economy.The domestic supply price index rose 31.6% on year in April, and by 3.1% from March, reported the agency.Singapore's domestic oil supply index rose 79.3% on year in April, but slipped 1.6% in March.The city-state's non-oil domestic supply index rose 17.1% on year in April, and by 5.4% from March.The Monetary Authority of Singapore, the city-state's de facto central bank, is slated to release a policy statement and macroeconomic outlook on July 31.Despite recent increases in producer prices, Singapore's core consumer price index inflation eased to a 1.4% on-year rise in April, down from 1.7% in March. The headline inflation rate remained unchanged at 1.8% on year, in the month.The MAS does have an explicit inflation target, but bank literature refers to inflation near 2% or below as "stable."

$^STI